Plan Nacional de Prevención, Control y Manejo de Cáncer Cervicouterino 2014-2024

Objectives

Guatemala’s 2014–2024 National Plan for the Prevention, Control and Management of Cervical Cancer aims to reduce cervical-cancer incidence and mortality among women through timely prevention, control, management and active community participation.[1]It responds to a major and inequitable health burden, particularly among women with limited resources, through a culturally appropriate, rights-based and participatory framework adapted to differing social, economic, cultural and environmental contexts.[2][3]

• Reduce cervical-cancer mortality by 25% and incidence by 30% over ten years, prioritising women at higher risk.[4]
• Achieve 80% screening coverage, provide definitive diagnosis and treatment locally for 80% of women with abnormal or positive screening results, and ensure timely follow-up through Early Detection Clinics and Cervical Pathology Units for 60% of women.[4]
• Strengthen health promotion, information, education and communication, advocacy, screening, definitive diagnosis, management of pre-neoplastic lesions and invasive cancer, palliative care, information systems, research, workforce training, and performance monitoring and evaluation.[3]
• Expand organised screening among women aged 25 to 54, while also offering it to women who have initiated sexual activity and have risk factors or request screening.[5]
• Use conventional cytology, visual inspection with acetic acid, human papillomavirus DNA testing, or sequential approaches according to service capacity and available resources.[5]
• Introduce human papillomavirus vaccination through agreed technical, operational and financing arrangements, supported by implementation protocols and stakeholder consensus.[6][7]
• Strengthen national cancer registration, epidemiological surveillance, case follow-up and indicator notification to inform decisions and reduce morbidity and mortality.[8]
• Build research and workforce capacity, including incorporation of cervical-cancer prevention, diagnosis and treatment into relevant undergraduate and postgraduate health curricula.[9][10]

Implementation

The plan uses a decentralised, integrated service model led by the Ministry of Public Health and Social Assistance, with local committees tailoring prevention and early-detection actions to community needs and resources.[3]It links community mobilisation and screening with diagnostic, treatment, referral, rehabilitation and palliative-care services across levels of care, while coordinating public institutions, social security, specialised cancer services, civil society, academia, municipalities and private providers.[11][12]

• Coordinate implementation through the Ministry of Public Health and Social Assistance and the National Reproductive Health Programme, alongside local committees, the Guatemalan Social Security Institute, the National Cancer Institute, non-governmental organisations, universities, municipalities, community leaders and cooperating organisations.[6][13][12]
• Establish interdisciplinary local, departmental and regional committees to assess needs, organise community participation, develop locally appropriate information and education strategies, and support prevention and management activities.[3][14]
• Deliver communication and education through schools, communities, mass media, printed materials, mobile-phone messaging, internet and locally appropriate channels, engaging women, partners, families, adolescents, religious groups and community leaders.[14][15]
• Operate Screening Centres in community facilities, health posts, health centres, outpatient services and hospitals, with responsibilities for promotion, active case-finding, test processing and mobilisation of local prevention committees.[16]
• Use screen-and-treat services with certified personnel, visual inspection with acetic acid and cryotherapy where capacity permits, particularly for populations likely to be lost to follow-up.[5]
• Standardise sample submission, test-result notification, referral documentation and counter-referral procedures, while using mobile clinics and outreach to address access barriers.[17]
• Organise Cervical Pathology Units as intermediate referral and counter-referral centres with specialised clinical, nursing and social-work staff, laboratory support, diagnostic equipment and capacity to manage cervical lesions.[18]
• Refer women requiring more complex care to higher-level hospitals and specialised services, with the National Cancer Institute serving as the principal public-sector referral centre for advanced cases requiring radiotherapy and chemotherapy.[19][12]
• Strengthen treatment capacity through equipment, staffing, infrastructure, medicines, maintenance systems, specialised surgery, radiotherapy, rehabilitation and palliative-care units.[20][21][22]
• Procure palliative medicines, including opioids, through the Pan American Health Organization and World Health Organization Strategic Fund, alongside regulatory review and measures to improve medicine access.[13]
• Maintain unified hospital, clinical, cytology and histopathology records; standardise reporting; establish population-based cancer registration; and integrate surveillance with the national health information system.[8][23]
• Monitor implementation through component-specific actions, indicators and expected results, with a proposed programme manager coordinating implementation and preparing an annual progress report against plan targets.[24][12]
• Track screening coverage, test positivity, treatment rates, functioning laboratory networks, referral performance, trained personnel, service quality, treatment access, palliative-care capacity and research outputs.[25][26][27]
• Mobilise financing for programme operation, infrastructure, equipment, training, research, radiotherapy and vaccination, although the supplied material does not specify a consolidated budget, funding gap or overall financing framework.[18][28][29][6]

Monitoring & Evaluation

The plan establishes monitoring, evaluation, information systems, case follow-up and indicator notification as core components of Guatemala’s 2014–2024 cervical cancer response. It links performance assessment to prevention, screening, diagnosis, treatment, palliative care, research and workforce development, while assigning coordination roles primarily to the Ministry of Public Health and Social Assistance (MSPAS) and the National Reproductive Health Programme.[24][1][3][8][23]

• Strengthen and unify hospital, clinical, cytology and histopathology records; formalise reporting of screening, diagnosis and treatment results; and use an early-detection card to support case follow-up.[8][23]
• Implement epidemiological surveillance for pre-neoplastic lesions and cervical cancer, establish a population-based cervical and breast cancer registry, and publish and disseminate registry findings.[8][23]
• Monitor component implementation through indicators, expected results and responsible actors, including local committees’ systematic assessment of needs, activities and processes.[3][30]
• Track national outcome targets of a 25% reduction in cervical-cancer mortality, a 30% reduction in incidence, 80% screening coverage, definitive diagnosis and treatment for 80% of women with abnormal or positive screening results, and timely follow-up for 60% of women through Early Detection Clinics and Cervical Pathology Units.[4]
• Measure screening and treatment performance through coverage among people aged 25 to 54 years, screening-test positivity and treatment rates, alongside standards for organisation, service quality, target achievement and disease-burden reduction.[26]
• Assess screening-service implementation through clinic action plans, units organised into networks, institutional screening policies, women screened following coverage-enhancement strategies, distributed standards and personnel trained.[17][31]
• Monitor diagnostic and laboratory capacity through functioning laboratory networks, patient-care records integrated with health information systems, and the operation of referral and counter-referral arrangements.[18][25]
• Track treatment capacity through pre-neoplastic lesion units improved, personnel recruited and trained, supplies available, maintenance services operating, treatment units strengthened, imaging centres and molecular biology laboratories available.[28][19][29]
• Monitor surgical, radiotherapy, rehabilitation and palliative-care services through equipped operating theatres, trained personnel, radiotherapy equipment and patients treated, functioning dosimetry equipment, rehabilitation units, specialist teams, palliative-care units and support networks.[21][32][22][13][33]
• Evaluate information, education and communication activities through materials produced, media communications and campaigns, education interventions and participants; assess advocacy through relevant legal and policy documents; and assess human papillomavirus vaccine readiness through normative documents and implementation protocols.[14][15][7]
• Monitor research and training through functioning research groups, proposals, network participation, approved projects, completed investigations, registered publications, personnel trained and training support obtained.[9][34][10]
• Use colposcopy-clinic indicators covering productivity, access, timeliness, effectiveness, quality, reliability and interaction with linked facilities. Benchmarks include 100% infrastructure, biopsy, treatment and referral coverage; over 80% service-capacity utilisation; over 85% one-year follow-up; and over 95% therapeutic success.[27][35]
• Require a cervical cancer programme manager to coordinate implementation, monitor and evaluate the plan, and prepare and disseminate an annual report on achievements and progress towards targets.[12]

Available evidence identifies limitations in official reporting and the absence of a population-based registry integrated with epidemiological surveillance, although surveillance also draws on the cancer institute hospital registry, the Health Management Information System, the National Epidemiological Surveillance System and GLOBOCAN estimates.[36][37][33]Detailed reporting schedules, independent evaluation arrangements, sanctions and wider accountability procedures are generally not specified beyond named responsible institutions, monitoring standards and the proposed annual progress report.[31][21][32][22][12]

Costing & Financing

The plan identifies substantial resource requirements across prevention, screening, diagnosis, treatment, palliative care, information systems, research, training and monitoring, but most supplied sections do not provide a comprehensive budget, costing methodology, funding-gap analysis, financing allocations or economic assumptions.[17][25][21][32][22][8][23]

• Allocate Ministry of Public Health and Social Assistance funding to the National Cancer League under the service agreement for patients referred from public health services; the reported 2013 allocation was 21,000,000 Quetzales.[38]
• Establish financing for operation of the national early-detection programme in line with assigned responsibilities and activities, although no amount or funding source is specified.[18]
• Mobilise resources for diagnostic and treatment equipment, laboratory supplies, staffing, infrastructure upgrades, mobile services, training, and preventive and corrective maintenance.[16][20][39]
• Seek financial support to improve pre-neoplastic lesion units and international support for radiotherapy capacity, cancer-treatment access and a national radiotherapy centre. Potential partners include the World Bank, Inter-American Development Bank, Pan American Health Organization, World Health Organization and other cooperating agencies.[28][29][21]
• Use the Pan American Health Organization and World Health Organization Strategic Fund to procure cancer and palliative-care medicines, including opioids, with the stated aim of reducing medicine costs and improving access.[29][13]
• Seek financing and technical assistance for cervical-cancer research and workforce training through cooperating, national and international organisations.[9][10][26]
• Plan sustainable financing before introducing human papillomavirus vaccination, informed by a 2013 cost-effectiveness study of bivalent and quadrivalent vaccines.[6][30]
• Ensure that screening is undertaken only where resources are sufficient to provide definitive diagnosis and treatment for positive cases, and where disease prevalence justifies screening costs and effort.[7]

Explicit financial figures in the supplied material include reported amounts for research consultancy, non-governmental organisation training and application of monitoring and evaluation standards, but their currency, funding source, budget period and underlying assumptions are not specified.[12]A human papillomavirus DNA self-sampling pilot was planned with 110,000 tests from August 2014, but no associated cost is given.[7][5]